“We launched 16 new products, made steady progress on our robotics project, and successfully completed the acquisition of Transplant Technologies of Texas,” said Chairman and CEO David Paul. “This performance was the result of continued execution of our strategy of robust product innovation, sales force expansion and disciplined expense control.”
Here are five things to know about the company’s financial report:
1. Worldwide sales for the fourth quarter were $128 million, an 11.8 percent increase over the same period last year. Full year sales were up 9.2 percent to $474 million.
2. Net income in the fourth quarter was $27.6 million. The net income for the 2014 full year was $92.5 million.
3. The company reported cash, cash equivalents and marketable securities ended the year at $304.1 million. This is a $28.6 million increase throughout the year.
4. Globus Medical is still debt free.
5. The Non-GAAP Adjusted EBITDA was 36.7 percent of sales.
More articles on orthopedic devices:
NuVasive’s 2014 revenue up 11.3%: 10 key notes
ChoiceSpine brings former Alphatec, TranS1 execs onboard—5 things to know
McGinley Orthopaedic Innovations’ surgical drill receives FDA clearance
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
